C07D207/277

HEPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:


X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

QUATERNARY HETEROATOM CONTAINING COMPOUNDS

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II):

##STR00001##

comprising treating a compound of Formula (I):

##STR00002##

with a transition metal catalyst and under alkylation conditions as valence and stability permit.

QUATERNARY HETEROATOM CONTAINING COMPOUNDS

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II):

##STR00001##

comprising treating a compound of Formula (I):

##STR00002##

with a transition metal catalyst and under alkylation conditions as valence and stability permit.

Compound and modified conjugated diene-based polymer including functional group derived therefrom

The present invention relates to a compound represented by Formula 1, a method for preparing the same, and a modified conjugated diene-based polymer having a high modification ratio and including a functional group derived from the compound.

Compound and modified conjugated diene-based polymer including functional group derived therefrom

The present invention relates to a compound represented by Formula 1, a method for preparing the same, and a modified conjugated diene-based polymer having a high modification ratio and including a functional group derived from the compound.

Difluoroketamide derivatives as HTRA1 inhibitors

The invention provides novel compounds having the general formula (I) ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, A, X and R.sup.11 are as described herein, compositions including the compounds and methods of using the compounds.

Difluoroketamide derivatives as HTRA1 inhibitors

The invention provides novel compounds having the general formula (I) ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, A, X and R.sup.11 are as described herein, compositions including the compounds and methods of using the compounds.

CROSS-LINKING AGENT(S)
20210130292 · 2021-05-06 ·

Cross-linking agent(s), composition(s) made therefrom and use(s) thereof. For example, crosslinking agent(s) that are used to make composition(s) such as hydrogel material(s). Such materials are useful in the manufacture of biocompatible medical devices, for example, hydrogel materials having desirable physical properties for use as contact lense(s) and/or stimulating device(s).

CROSS-LINKING AGENT(S)
20210130292 · 2021-05-06 ·

Cross-linking agent(s), composition(s) made therefrom and use(s) thereof. For example, crosslinking agent(s) that are used to make composition(s) such as hydrogel material(s). Such materials are useful in the manufacture of biocompatible medical devices, for example, hydrogel materials having desirable physical properties for use as contact lense(s) and/or stimulating device(s).

PYRROLIDINONES AND A PROCESS TO PREPARE THEM
20210107890 · 2021-04-15 ·

This application is directed to a compound of Formula II Also disclosed is a process for preparing a compound of Formula II comprising using the compounds of Formulae IV and V Also disclosed is a method for preparing a compound of Formula I comprising contacting a compound of Formula II with a compound of a compound of Formula VI wherein A.sup.1, A.sup.2 A.sup.3, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4, B.sup.1, B.sup.2 and B.sup.3, are as defined in the disclosure.

##STR00001##